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Xiao-Jun Huang, Ying-Jun ChangExtensive ex vivo T cell-depleted or unmanipulated haploidentical transplantation provides benefits of rapid and
near universal donor availability for patients without HLA-identical sibling donors or those who urgently need
transplant. However, CD34 selected haplotype mismatched transplantation was limited by delayed immune
reconstitution (IR), although this protocol has now been an acceptable approach. Recently, Peking University
researchers developed a novel approach toHLA-mismatched/haploidentical blood andmarrow transplantation
without in vitro T cell depletion (GIAC protocol). This review summarizes transplant outcomes, and factors
correlating with transplant outcomes following the GIAC protocol. Moreover, future challenges in improving
posttransplant IR and finding the best approach reducing the incidence and severity of GVHD, whereas preserv-
ing graft-versus-leukemia effect to prevent the recurrence of underlying malignancy, are also discussed.
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plant outcome, Donor lymphocyte infusionINTRODUCTION
During the past 2 decades, substantial progress has
been made in the field of human leukocyte antigen
(HLA)-mismatched/haploidentical hematopoietic stem
cell transplantation (HSCT). Several transplant proto-
cols has been established worldwide [1-8]. In Perugia,
Italy, Aversa et al. [7-9] employed extensive ex vivo T
cell depletion and megadose stem cells that had
successfully overcome the HLA barrier to engraftment
in mice and humans. By this technique, engraftment
was improved and graft-versus-host disease (GVHD)
was reduced following haploidentical transplantation.
However, graft manipulation is associated with pro-
longed immune deficiencies and increased risks of
infectious complication [4]. To overcome these short-
comings, unmanipulated allografts and posttransplant
immune suppression were focused on by researchers
from Johns Hopkins University [10,11], Osaka
University [12], and other transplant centers [13,14].
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although more patients and a longer follow-up are
needed for confirmation [10-15]. In recent years,
Peking University researchers developed a novel
approach to HLA-mismatched/haploidentical blood
and marrow transplantation without in vitro T cell
depletion (the GIAC protocol) [6,15,16]. The
protocol entails the following: treating donors with
granulocyte colony-stimulating factor (G-CSF) to
induce donor immune tolerance, intensified immuno-
logic suppression to both promote engraftment and
to prevent GVHD, antithymocyte globulin (ATG)
was included for the prophylaxis of GVHD and graft
rejection, and combination of G-CSF-primed bone
marrow harvest (G-BM) and G-CSF-mobilized pe-
ripheral blood stem cell harvest (G-PB) as the source
of stem cell grafts. Via this GIAC protocol, promising
results have been achieved (Table 1) [5,6,15,17].
Currently, the status of haploidentical HSCT in
Europe Japan, and the United States has been
reviewed by other researchers [2,9,18-23]. Therefore,
this review examined the basic and clinical research
on unmanipulated haploidentical blood and marrow
transplantation in China [6,24-27], especially at
Peking University [5,6,15-17,27-38].IMMUNE TOLERANCE BASIS FOR
UNMANIPULATED HAPLOIDENTICAL
BLOODAND MARROW HSCT
The use of G-BM and G-PB may play a critical
role in the GIAC protocol, although several197
Table 1. Studies on HLA-Mismatched/Haploidentical Hematopoietic Stem Cell Transplantation
Patients (n) Disease Conditioning GVHD Prophylaxis GR aGHVD
cGVHD
Limited
Extensive TRM Relapse LFS Reference
35 AML/ALL/CML/
DLBCL/ATL
Standard intensity ± TBI
Reduced intensity ±
ATG
Tacrolimus based 0 56% 19%
64%
11 pt 9 pt 40% Ichinohe et al. (2004)
171 ALL/AML/CML/MDS Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 0 55% 21.3%
23.3%
19% SR @ 2 years
31% HR @ 2 years
SR 12%
HR 39%
SR 68% @ 2 years
HR 42% @ 2 years
Huang et al. (2006)
135 ALL/AML/CML/MDS Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 1.5% (II-IV)
40%
55% 22% 18% 64% @ years Lu et al. (2006)
68 AML/ALL/CML/MDS/
CLL/HL/NHL/MM/
PNH
TBI/Cy/Flu Cy/MMF/Tacrolimus 13% (II-IV)
34%
5% *
25%
4% @ 100 days
15% @ 1 year
51% @ 1 year
58% @ 2 years
34% @ 1 year
26% @ 2 years
Luznik et al. (2008)
29 AML/ALL/CML/NHL/
MM
Flu/Mel/OKT3/
thiotepa
CD3/CD19 depletion 1 pt (II-IV)
48%
3 pt 20% @ 100 days 12 pt 35% @ 1 year Bethge et al. (2008)
42 AML/ALL/CML Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 0 57.2% 27.2%
29.5%
20.4 ± 6.5% @ 1 year 21.43% 57.3±8% @ 3 years Liu et al. (2008)
93 CML Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 0 64.25% 27.16%
22.22%
28.3% @ 1 year
16.92% @ 1 year
13.33% @ 1 year
7.69% @ 1 year
CP1 3.77%
CP2 0%
AP 13.94%
BC 38.46%
76.5% @ 1 year
74.5% @ 4 years
Huang et al. (2008)
45 AML/ALL/CML/NHL TBI/Cy/Ara-C/ATG CsA/MTX/MMF/ATG 2 pt (II-IV)
5 pt
9 pt
3 pt
3 pt 11 pt 24 pt Wang et al. (2009)
46 AML/CML/ALL TBI/Cy/Ara-C/ATG
Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 0 (I-II)
43.5%
10.9% 8.7% @ 2 years 23.9% @ 2 years 70.6% @ 2 years Chen et al. (2009)
250 AML/ALL Bu/Cy/Ara-C/
MeCCNU+ATG
CsA/MTX/MMF 0 45.8% 31.3%
22.6%
SR
AML 11.9% @ 3 years
ALL 24.3% @ 3 years
HR
AML 20.2% @ 3 years
ALL 48.5% @ 3 years
SR
AML 19.4% @ 3 years
ALL 21.2% @ 3 years
HR
AML 29.4% @ 3 years
ALL 50.8% @ 3 years
SR
AML70.7% @ 3 years
ALL 59.7% @ 3 years
HR
AML 55.9% @ 3 years
ALL 24.8% @ 3 years
Huang et al. (2009)
HLA indicates human leukocyte antigen; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; DLBCL, diffuse large B cell lymphoma; ATL, adult T cell leukemia/
lymphoma; MDS, myelodysplastic syndrome; TBI, total body irradiation; pt, patient; ATG, anti thymocyte globulin; Bu, busulfan; Cy, cyclophosphamide; GVHD, graft-versus-host diease; CsA, cyclosporine A; MMF,
mycophenolate mofetil; Flu, fludrabine; SR, standard risk; HR, high risk; GR, graft failure; aGVHD, acute GVHD; cGVHD, chronic GVHD; TRM, treatment-related mortality; LFS, leukemia-free survival; CP, chronic
phase; AP, accelerated phase; BC, blast crisis.
* indicates the incidence of extensive cGVHD at 1 year in the patients who received 2 doses of posttransplantation Cy.
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Biol Blood Marrow Transplant 17:197-204, 2011 199Haploidentical Blood and Marrow HSCTmechanism involving in the overcome of HLA bar-
rier [6,27,39-42]. Initial studies showed that G-
CSF leads to T cell hyporesponsiveness and
modulates the balance between Th1 and Th2
immune responses (Figure 1) [39,41-44]. The
effect of G-CSF on T cells is originally believed to
be mediated exclusively through other effector
cells, such as monocytes, CD401 GM cells, and
type 2 dendritic cells (DC2, plasmacytoid DCs)
[39,41,43]. Franzke et al. [45] reported that G-CSF
can directly modulate T cell immune responses via
G-CSF receptor. Morris et al. [46] suggest that 3
key immunomodulatory effects after treating healthy
donors with G-CSF may lead to the attenuation of
GVHD. First, donor T cells upregulate GATA-3
expression and are biased toward Th2 differentia-
tion, limiting Th1-dependent monocyte activation
after stem cell transplantation (SCT). Second, G-CSF
induces the generation of Tr1 regulatory cells
through interleukin-10 (IL-10) production. Third,
G-CSF expands regulatory antigen-presenting cells
(APCs) within the donor (immature myeloid precur-
sors and plasmacytoid DCs) which, after transplanta-
tion, promote the generation of classical CD41
CD251 IL-10-producing regulatory T cells (Tregs).
The generation of IL-10 and transforming growth
factor-b (TGF-b) from Tr1 and Treg serve to further
inhibit the inflammatory effector phase of GVHD,
limiting target tissue damage [46].
In human and mice studies, the effects of G-CSF
on immune characteristics of BM grafts were demon-
strated by other researchers and us [41,44]. Our data
suggest that in vivo administration of G-CSF might
alter the composition of BM grafts, polarize Th1 to
Th2, and induce hyporesponsiveness of T cells [41].
More recently, we found that G-CSF treament signif-
icantly decreased the expression of VLA-4, ICAM-1,Figure 1. Immunoregulatory effects after G-CSF administration to healthy do
and regulatory T cell (Treg) functional profile is depicted schematically. G-CSF
precursors, and induce tolerogenic dendritic cells (DCs). The numbers of mono
the effects of G-CSF were observed both in peripheral blood and bone marroL-selectin, and LFA-1 on naı¨ve CD41 and CD81 T
cells in BM grafts. G-CSF also polarized BM-naı¨ve
CD41 and CD81T cells from Th1 to Th2 phenotype
[44]. Our findings also suggest that lower T cell hypo-
responsiveness and easier polarization of T cells from
Th1 to Th2 are found in G-BM compared with G-
PB [42].
To clarify the mechanism on clinical use of G-BM
andG-PB, these 2 grafts were mixed in vitro according
to the proportions of G-PB:G-BM equal to 2:1, 1:1,
and 1:2, respectively [40]. This match the clinical
data, in which the median ratio of G-PB:G-BM was
1.16 (range: 0.15-5.73). Our results suggest that T
cell hyporesponsiveness and polarization of T cell
from Th1 to Th2 could be maintained after in vitro
mixture of G-PB and G-BM. Although the relevance
of this highly simplified in vitro system with phytohe-
magglutinin to the complex situation of in vivo allor-
eactivity cannot be completely established, we think
that our data might partly explain the comparable
incidence of GVHD beween HLA-mismatched/
haploidentical blood and marrow transplantation and
HLA-identical sibling transplant (Figure 1) [5,6,40].
Other factors contributing to the overcoming of
HLA barriers includes: (1) the use of ATG before
transplantation, which may induce depletion of
infused donor T lymphocytes in vivo and thus lower
the incidence of GVHD [47]; (2) possible effect of
combination of cyclosporine A (CsA), methotrexate
(MTX), and mycophenolate mofetil (MMF) as
postgrafting immunosuppression [48]; (3) the applica-
tion of G-CSF day 15 posttransplant, which may
further regulate T cell function [5,15]; (4) the
immunomodulatory effect of mesenchymal stem cells
(MSCs)/mesenchymal (stroma) progenitor cells
(MPCs) from the G-CSF stimulated BM and
peripheral blood stem cells (PBSCs), respectively [5,6].nors. The G-CSF-induced alteration of immune cells, T cell polarization,
can skrew the phenotype of T cells from Th1 to Th2, expand myeloid
cyte and plasmacytoid DCs (DC2) were selectively increased. *Indicates
w grafts.
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Engraftment
In the GIAC protocol, the median time for mye-
logenous engraftment was 12 days (range: 9-26 days)
and for platelet 15 days (range: 8-151 days) [5]. There
was no significant association between the extent of
HLA disparity and the time of myeloid or platelet re-
covery following HLA-mismatched/haploidentical
transplantation [5,6,17,29]. Chang et al. [29] showed
that low number of CD341 cells (\2.19  106/kg) in
allografts, and advanced disease stage were indepen-
dently associated with an increased risk of platelet
engraftment. Although in pediatric patients [28],
only infused CD341 cells/kg of recipient weight
were significantly associated with an increased risk of
platelet engraftment. These results suggest that
a higher number of CD341 cells in allografts should
be preferred to ensure rapid platelet engraftment,
especially in patients with advanced stage disease
because the latter is also associated with delayed plate-
let recovery in our transplant setting [28,29]. In the
Italy series, primary engraftment was achieved in 94
of 101 assessable patients. Six of the 7 patients who
rejected the primary graft engrafted after a second
transplantation. Neutrophils reached a mean of
1000/mm3 at a median of 11 days (range: 9-30
days). Platelets reached 25,000/mm3 and 50,000/
mm3 at medians of 15 and 16 days, respectively
(range: 11-45 days, and 11-110 days, respectively)
[8]. Bethge et al. [49,50] demonstrated that
engraftment was rapid with a median time to .500
granulocytes/mL of 12 (range: 10-21) days and
.20,000 platelets/mL of 11 (range: 7-38) days
following haploidentical transplantation in adults
using CD3/CD19 depletion and reduced-intensity
conditioning (RIC).GVHD
Our initial study showed that, at 100 days post-
transplantation, the cumulative incidence was 55.0%
for grade II-IV acute GVHD (aGVHD), and 23.1%
for grade III-IV aGVHD. The incidence of chronic
GVHD (cGVHD) was 44.67%, with 21.3% for
limited and 23.3% for extensive, respectively [5].
Similar incidence of aGVHD and cGVHD was ob-
served in subgroups of patients, including pediatrics
and those with chronic myelogenous leukemia
(CML) or acute leukemia [15-17]. Factors associated
with a significantly increased risk of aGVHD include
a higher CD4/CD8 cell ratio (more than 1.16) in G-
BM [35,51] and CD56bright NK cells (more than 41.9
 106/kg) in allografts [36]. Although a higher
CD56dim/CD56bri NK cell ratio (more than 8.0) in al-
lografts was correlated with a decreased risk of III-IVaGVHD [36], further study showed that a high cell
dose of CD41CD45RA1CD62L1 cells in allografts
increase the incidence of grades II-IV aGVHD after
unmanipulated blood and marrow transplantation
[52]. This finding is interesting and important be-
cause selectively depletion of CD41CD62L1 naı¨ve
cells in allografts might decrease the development
of GVHD in the ‘‘GIAC’’ transplant settings if our
preliminary results could be confirmed in future
studies.
Other studies demonstrated that severe aGVHD
and extensive cGVHD were largely prevented using
CD3/CD19depletionor positive selectionCD341 cells
from leukapheresis [8,49,50]. In this unmanipulated
haploidentical transplant setting the incidence of
grade III-IV aGVHD and extensive cGVHD were ac-
ceptable, although the T cell dose in grafts was more
than 100  106/kg [5,6,15,27]. Moreover, comparable
incidences of GVHD were found between patients
who underwent haploidentical transplantion and those
after HLA-identical sibling or unrelated HSCT
[6,25,27]. These findings may be related to several
factors (please see the section: immune tolerance basis
for unmanipulated haploidentical blood and marrow
HSCT).
In our transplant protocol [5,6,15-17,27], no effect
of noninheritedmaternal antigen (NIMA)-mismatched
siblings on GVHD was found as previously described
by Ichinohe et al. [13] and von Rood et al. [14]. Several
reasons may account for this different result: (1) all pa-
tients, except for 1 who receive bone marrow plus pe-
ripheral blood grafts, in Ichinohe or van Rood’s studies
received peripheral blood grafts or bone marrow grafts
only [13,14]; (2) the application of G-CSF on day 5
posttransplant may contribute to the different result;
(3) the GIAC protocol was different from those
reported by Ichinohe et al. [13] and van Rood et al.
[14]; especially, that no ATG was included in their
transplant settings.Relapse and Management
The Peking University study evaluated 250 GIAC
recipients (acute myelogenous leukemia [AML] 108;
acute lymphoblastic leukemia [ALL] 142). Of the
250 patients, 45 (AML, 13; ALL, 32) relapsed after
transplantation; of these, 22 (AML, 6; ALL, 16) were
from the high-risk group. The 3-year probability of re-
lapse in the standard-risk group was 11.9% and 24.3%
for AML and ALL, respectively, and that in high-risk
group was 20.2% and 48.5% for AML and ALL, re-
spectively [15]. Comparison analysis showed that there
were no differences in relapse rate between patients
who underwent unmanipulated haploidentical trans-
plantation and those who received HLA-identical or
unrelated HSCT [6,25,27]. Three factors, including
advanced disease status [5,6,15,16], higher CD4/
Biol Blood Marrow Transplant 17:197-204, 2011 201Haploidentical Blood and Marrow HSCTCD8 in G-BM [35,51], and delayed lymphocyte
reovery at day 30 posttransplantation [31], are corre-
lated with increased relapse rates, whereas a higher
CD56dim/CD56bri NK cell ratio (more than 8.0) was
correlated with a decreased rate of relapse in the
GIAC protocol [36].
In contrast to other authors’ reports [53,54], we
found that the 3-year probability of relapse was
24.3% and 48.5% for ALL in the standard-risk and
high-risk group, respectively, following unmanipu-
lated haploidentical transplantation. It seems that the
relapse rate of ALL patients after unmanipulated
haploidentical transplant is lower than those who
underwent CD34 selected haplotype identical trans-
plantation, although there is deficient in comparabil-
ity. Several factors may be related to the result: (1)
some differences, including compositions in allogafts
and conditioning regimen, exist between CD34
selected haplotype identical transplant [53,54] and
the GIAC protocol [6,16,27,55]; (2) kinetics of NK
cell recovery and the role of NK cell alloreactivity of
are also different between these 2 haploidentical
transplant protocols [30,37,38,56,57]; and (3) the use
of modified donor lymphocyte infusion (DLI) for
prophylaxis of relapse in some patients following
GIAC protocol [33].
In HLA-matched, related, or unrelated HSCT
settings, DLI has been shown to exert a graft-
versus-leukemia (GVL) effect and has been success-
fully used for treatment of leukemia relapse, although
DLI could be followed by a high rate of severeGVHD
and, sometimes, pancytopenia and infection [58]. To
overcome these shortcomings, a modified DLI strat-
egy was adopted in our center [32,33]. Considering
the higher relapse rate of high-risk leukemia even af-
ter unmanipulated HLA-mismatched/hapolidentical
HSCT, we explored the possibility and demonstrated
the feasibility of applying the modified DLI strategy
against leukemia recurrence from therapeutic DLI
to prophylaxis DLI for patients with advanced hema-
tologic malignancies [32-34].Treatment-Related Mortality (TRM) and
Survival
Under the ‘‘GIAC’’ protocol, Huang et al. [5]
found that 39 of the 171 patients died from TRM.
The causes of nonrelapse death included GVHD in
13 cases, infection in 21 cases, and other causes in 5
cases such as heart failure and hepatic failure. The
TRM was also demonstrated in pediatric patients
and those with CML or acute leukemia (Table 1)
[17]. For CML patients, the 1-year TRM of patients
in CP1, CP2/CR2, AP, and BC are 28.3%, 16.92%,
13.33%, and 7.69%, respectively [16]. In a recent
report, 250 acute leukemia patients received allografts
from related donors. The 3-year TRM in standard-riskand high-risk groups was 19.4% and 29.4% for AML
and 21.2% and 50.8% for ALL, respectively [15].
Four factors, including advanced disease status
[5,15], higher CD4/CD8 in G-BM [35], time from
diagnosis to transplant (.450 day for CML patients)
[16], and lower absolute counts of lymphocytes
(#300/mL) are correlated with increased TRM follow-
ing unmanipulated haploidentical transplantation [31].
Zhao et al. [36] found that a higher CD56dim/CD56bri
NK cell ratio (more than 8.0) in allografts was corre-
lated with a decrease risk of TRM (P 5 .012).
As detailed in Table 1, the 2-year or 3-year proba-
bility of leukemia-free survival (LFS) for patients with
hematologic maliganancies ranged from 24.8% to
74.5% [5,6,15-17]. Superior LFS after unmanipulated
haploidentical transplantation is closely correlated
with early disease status [5,15,16], higher numbers of
CD56bright cells reconstituted day 14 posttransplant
[30], lower CD4/CD8 in G-BM [35], short time from
diagnosis to transplant (#450 days) for CML patients
[16], and higher absolute counts of lymphocytes
(.300/mL) day 30 posttransplant [31]. Similar LFS
were achieved using the GIAC protocol compared
withHLA-matched sibling transplantation or unrelated
donor transplantation [6,25,27]. A preliminary study
from the Tu¨bingen group showed that overall survival
(OS) is 9 of 29 patients with a median follow-up of
241 days (range: 112-1217) [50]. Rizzieri et al. [59] dem-
onstrated that the 1-year survival rate of 49 patients with
hematologic malignancies or marrow failure was 31%
(95% confidence interval [CI], 18%-44%) after nomye-
loablative therapy using haploidentical family member
donors.
Posttransplant Immune Reconstitution
At Peking University, the immune reconstitution
(IR) of natural killer (NK) cells in 43 patients were first
investigated [30]. Our results showed that the absolute
number of CD56bright NK subset in white blood cells
and number of CD56bright NK subset had recovered
to the donor’s level by day 14, and continuously
increased up to their highest levels by day 60 in those
[16] who never developed GVHD or by day 120 in
all 43 patients, which were higher compared with those
of healthy controls. The ratio of CD56dim/CD56bright
NK subsets in patients eventually reached the level
similar to that of healthy controls by day 120 in those
[16] who never developed GVHD, or by day 180 in all
43 patients. Patients with more CD56bright NK cells in
the recovery stage had a higher survival rate and the pa-
tients with a higher ratio of T/NK had a higher chance
of getting aGVHD and cGVHD [30].
In contrast to Ruggeri’s et al. results [53,54], our
findings showed that KIR ligand mismatch is
associated with higher aGVHD, a greater relapse
rate, and inferior survival [56]. The cumulative inci-
dence of 3-year LFS, OS, and TRM were best
202 Biol Blood Marrow Transplant 17:197-204, 2011X.-J. Huang and Y.-J. Changpredicted by the number of KIR ligands carried by pa-
tients (P5 .002 for LFS; P5 .014 for OS; P5 .030 for
TRM).We also found that the KIR ligand-ligand mis-
matchmodel is a good predictor of aGVHD (P5 .002)
38. Meanwhile, the presence of donor-activating
KIR2DS3 also contributed significantly to aGVHD
and cGVHD. These data suggest that prognosis after
transplantation is associated with the numbers of
KIR ligands in recipients and T cell alloreaction may
play a predominant role in the ‘‘GIAC’’ model. Zhao
et al. [37] also demonstrated that high levels of
CD94 expression in donors or in recipients by day 60
after transplantation might be a good predictor for
poor prognosis. Collectively, our results suggest that
the role of NK cell alloreactivity could be covered by
a large numbers of T cells in the GIAC protocol
[30,37,38].
A retrospective study suggest that the IR, espe-
cially CD41 cells, and CD41CD45RA1 cells, during
the first 6 months following HLA-mismatched/
haploidentical transplantation without in vitro T cell
depletion was somewhat delayed compared with those
after HLA-matched sibling transplant [60]. Currently,
a prospective study is being carried out in our center to
investigate the kinetics of T cell, dendritic cells,
and regulatory T cells after unmanipulated HLA-
mismatched/haploidentical transplantation.FUTURE DIRECTIONS
Several Chinese groups have confirmed the effeci-
acy and feasibility of HLA-mismatched/haploidentical
transplantation using an unmanipulated graft [24-26].
More recently, Huang et al. [27] showed that for every
major HSCT end point, including relapse, nonrelapse
mortality, and survival, partially matched-related and
-unrelated HSCT, are not significantly different.
This sudy provides better donor choice at experienced
transplant centers, especially under certain specialized
circumstances, and an opportunity for patients to ben-
efit from HSCT when a HLA matched donor is not
available. However, infection, relapse, and GVHD
are still the main complications leading to mortality
and morbidity after unmanipulated transplant. Based
on previous studies [16,17,27-38,51,52,56], there are
several novel approaches that may be promising in
the future: (1) selective but effective allodepletion of
CD41CD62L1 naı¨ve cells [52], which may facilitate
successful donor engraftment, improve posttransplant
IR, and maximally reduce the indidence of GVHD; (2)
determining the patients who will benefit from
immune-modulation therapy posttransplantation us-
ing prognosis index, such as Wilms’ tumour suppres-
sor gene (WT1), and day 130 absolute lymphocyte
counts [31]; (3) improving DLI, to acquire GVL effect
without or limiting GVHD; (4) further reducing inTRM after unmanipulated HLA-mismatched/
haploidentical transplantation should aim at poor prog-
nosis index [30,35,37,38] by hastening posttransplant
IR, using G/GM test and fungal PCR for early
diagnosis of fungal infection, and improving antifungal
efficancy with preemptive management strategy; and
(5) using adoptive cellular immunotherapy, such as
Tregs, NK/Tregs, MSCs, and donor-derived NK sub-
sets, as well as the third-party cells infusion.ACKNOWLEDGMENTS
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